참고문헌
- Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008;372:1263-71. https://doi.org/10.1016/S0140-6736(08)61522-6
- Vellodi A. Lysosomal storage disorders. Brit J Haematol 2005;128:413-31. https://doi.org/10.1111/j.1365-2141.2004.05293.x
- Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-8. https://doi.org/10.1001/archpedi.160.6.603
- Langeveld M, Elstein D, Szer J, Hollak CEM, Zimran A. Classifying the additional morbidities of Gaucher disease. Blood Cells Mol Dis 2018;68:209-10. https://doi.org/10.1016/j.bcmd.2016.12.006
- Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A. Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol 1984;65:99-109. https://doi.org/10.1007/BF00690463
- Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet 2011;20:1375-86. https://doi.org/10.1093/hmg/ddr019
- Shen HM, Mizushima N. At the end of the autophagic road: An emerging understanding of lysosomal functions in autophagy. Trends Biochem Sci 2014;39:61-71. https://doi.org/10.1016/j.tibs.2013.12.001
- Wei H, Kim SJ, Zhang Z, Tsai PC, Wisniewski KE, Mukherjee AB. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet 2008;17:469-77. https://doi.org/10.1093/hmg/ddm324
- Hong YB, Kim EY, Jung SC. Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: A possible role in the neuronal loss. J Hum Genet 2004;49:349-54. https://doi.org/10.1007/s10038-004-0155-2
- Finn LS, Zhang M, Chen SH, Scott CR. Severe type II Gaucher disease with ichthyosis, arthrogryposis and neuronal apoptosis: Molecular and pathological analyses. Am J Med Genet 2000;91:222-6. https://doi.org/10.1002/(SICI)1096-8628(20000320)91:3<222::AID-AJMG13>3.0.CO;2-#
- Liu KP, Zhou D, Ouyang DY, Xu LH, Wang Y, Wang LX, et al. LC3B-II deacetylation by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation. Biochem Biophys Res Commun 2013;441:970-5. https://doi.org/10.1016/j.bbrc.2013.11.007
- Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005;280:40282-92. https://doi.org/10.1074/jbc.M508786200
- Kim C, Choi H, Jung ES, Lee W, Oh S, Jeon NL, et al. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 2012;7:e42983. https://doi.org/10.1371/journal.pone.0042983
- Yang C, Rahimpour S, Lu J, Pacak K, Ikejiri B, Brady RO, et al. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci U S A 2013;110:966-71. https://doi.org/10.1073/pnas.1221046110
- Chuang WL, Pacheco J, Zhang XK, Martin MM, Biski CK, Keutzer JM, et al. Determination of psychosine concentration in dried blood spots from newborns that were identified via newborn screening to be at risk for Krabbe disease. Clin Chim Acta 2013;419:73-6. https://doi.org/10.1016/j.cca.2013.01.017
- Chuang WL, Pacheco J, Cooper S, McGovern MM, Cox GF, Keutzer J, et al. Lyso-sphingomyelin is elevated in dried blood spots of Niemann-Pick B patients. Mol Genet Metab 2014;111:209-11. https://doi.org/10.1016/j.ymgme.2013.11.012
- Gelb MH, Scott CR, Turecek F. Newborn screening for lysosomal storage diseases. Clin Chem 2015;61:335-46. https://doi.org/10.1373/clinchem.2014.225771
- Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 1982;39:709-18. https://doi.org/10.1111/j.1471-4159.1982.tb07950.x
- Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, et al. The French Gaucher's disease registry: Clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis 2012;7:77. https://doi.org/10.1186/1750-1172-7-77
- Berger J, Stirnemann J, Bourgne C, Pereira B, Pigeon P, Heraoui D, et al. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable. Br J Haematol 2012;157:274-7. https://doi.org/10.1111/j.1365-2141.2011.08989.x
- Yoshida S, Kido J, Matsumoto S, Momosaki K, Mitsubuchi H, Shimazu T, et al. Prenatal diagnosis of Gaucher disease using next-generation sequencing. Pediatr Int 2016;58:946-9. https://doi.org/10.1111/ped.13069
- Vigan M, Stirnemann J, Caillaud C, Froissart R, Boutten A, Fantin B, et al. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model. Orphanet J Rare Dis 2014;9:95. https://doi.org/10.1186/1750-1172-9-95
- Fuller M, Szer J, Stark S, Fletcher JM. Rapid, singlephase extraction of glucosylsphingosine from plasma: A universal screening and monitoring tool. Clin Chim Acta 2015;450:6-10. https://doi.org/10.1016/j.cca.2015.07.026
- Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response. Blood 2011;118:e118-27. https://doi.org/10.1182/blood-2011-05-352971
- Rolfs A, Giese AK, Grittner U, Mascher D, Elstein D, Zimran A, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One 2013;8:e79732. https://doi.org/10.1371/journal.pone.0079732
- Hamler R, Brignol N, Clark SW, Morrison S, Dungan LB, Chang HH, et al. Glucosylceramide and glucosylsphingosine quantitation by liquid chromatographytandem mass spectrometry to enable in vivo preclinical studies of neuronopathic Gaucher disease. Anal Chem 2017;89:8288-95. https://doi.org/10.1021/acs.analchem.7b01442
- Tylki-Szymanska A, Szymanska-Rozek P, Hasinski P, Lugowska A. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight. Mol Genet Metab 2018;123:495-500. https://doi.org/10.1016/j.ymgme.2018.02.004
- Vaccaro AM, Muscillo M, Suzuki K. Characterization of human glucosylsphingosine glucosyl hydrolase and comparison with glucosylceramidase. Eur J Biochem 1985;146:315-21. https://doi.org/10.1111/j.1432-1033.1985.tb08655.x
- Westbroek W, Nguyen M, Siebert M, Lindstrom T, Burnett RA, Aflaki E, et al. A new glucocerebrosidasedeficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease. Dis Model Mech 2016;9:769-78. https://doi.org/10.1242/dmm.024588
- Hein LK, Meikle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab 2007;92:336-45. https://doi.org/10.1016/j.ymgme.2007.08.001
- Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: A model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis 2003;14:595-601. https://doi.org/10.1016/j.nbd.2003.08.016
- Farfel-Becker T, Vitner EB, Futerman AH. Animal models for Gaucher disease research. Dis Model Mech 2011;4:746-52. https://doi.org/10.1242/dmm.008185
- Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Mansson JE, Ehinger M, et al. Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci U S A 2007;104:17483-8. https://doi.org/10.1073/pnas.0708086104
- Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med 2014;20:204-8. https://doi.org/10.1038/nm.3449
- Lugowska A, Hetmanczyk-Sawicka K, Iwanicka-Nowicka R, Fogtman A, Ciesla J, Purzycka-Olewiecka JK, et al. Gene expression profile in patients with Gaucher disease indicates activation of inflammatory processes. Sci Rep 2019;9:6060. https://doi.org/10.1038/s41598-019-42584-1
- Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000;96:1969-78. https://doi.org/10.1182/blood.v96.5.1969.h8001969_1969_1978
- Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99. https://doi.org/10.1038/nrd772
- Wang Y, Wang X, Liu L, Wang X. Hdac inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci Lett 2009;467:212-6. https://doi.org/10.1016/j.neulet.2009.10.037
- Kim SJ, Lee BH, Lee YS, Kang KS. Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor. Biochem Biophys Res Commun 2007;360:593-9. https://doi.org/10.1016/j.bbrc.2007.06.116
- Seo J, Jo SA, Hwang S, Byun CJ, Lee HJ, Cho DH, et al. Trichostatin A epigenetically increases calpastatin expression and inhibits calpain activity and calciuminduced SH-SY5Y neuronal cell toxicity. FEBS J 2013;280:6691-701. https://doi.org/10.1111/febs.12572
- Barkhuizen M, Anderson DG, Grobler AF. Advances in GBA-associated Parkinson's disease-Pathology, presentation and therapies. Neurochem Int 2016;93:6-25. https://doi.org/10.1016/j.neuint.2015.12.004
- Lu J, Yang C, Chen M, Ye DY, Lonser RR, Brady RO, et al. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci U S A 2011;108:21200-5. https://doi.org/10.1073/pnas.1119181109
- Kitatani K, Wada M, Perry D, Usui T, Sun Y, Obeid LM, et al. Activation of p38 Mitogen-Activated Protein Kinase in Gaucher's Disease. PLoS One 2015;10:e0136633. https://doi.org/10.1371/journal.pone.0136633
- Khan S, Jena G. Sodium butyrate, a Hdac inhibitor ameliorates eNOS, iNOS and TGF-beta1-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats. Food Chem Toxicol 2014;73:127-39. https://doi.org/10.1016/j.fct.2014.08.010
- Kaliszczak M, Trousil S, Ali T, Aboagye EO. AKT activation controls cell survival in response to HDAC6 inhibition. Cell Death Dis 2016;7:e2286. https://doi.org/10.1038/cddis.2016.180